Core Viewpoint - Hendi Pharmaceutical (301211.SZ) reported a decline in revenue and net profit for the first half of 2025, indicating ongoing financial challenges for the company [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 235 million yuan, a year-on-year decrease of 2.93% [1] - The net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 4.42 million yuan, a decline of 93.21% year-on-year [1] - The net cash flow from operating activities was 8.40 million yuan, down 73.71% year-on-year [1] - In 2024, the company reported operating revenue of 446 million yuan, a decrease of 32.75% year-on-year [1] - The net profit attributable to shareholders for 2024 was 91.55 million yuan, down 48.02% year-on-year [1] - The net profit after deducting non-recurring gains and losses for 2024 was 72.95 million yuan, a decline of 57.14% year-on-year [1] - The net cash flow from operating activities for 2024 was 96.07 million yuan, down 29.91% year-on-year [1] IPO and Fundraising - The total amount raised from the initial public offering (IPO) was 1.548 billion yuan, with a net amount of 1.401 billion yuan, exceeding the original target by 210 million yuan [2] - The company initially planned to raise 1.19 billion yuan for various projects, including the production of ibuprofen and other active pharmaceutical ingredients [2] - The IPO expenses amounted to 147 million yuan, with underwriting fees of 132 million yuan [2] Stock Actions - On May 24, 2023, the company announced a stock bonus plan of 2 shares for every 10 shares held, along with a pre-tax dividend of 4 yuan [3] - On August 1, 2025, the company announced a new stock bonus plan of 4.5 shares for every 10 shares held [4]
破发股亨迪药业1年1期净利连降 2021年上市募15.48亿